Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Rating of “Moderate Buy” by Brokerages

Stoke Therapeutics, Inc. (NASDAQ:STOK) has received a consensus rating of “Moderate Buy” from the ten research firms that are covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $37.10.

Several research firms have recently weighed in on STOK. HC Wainwright boosted their target price on Stoke Therapeutics from $35.00 to $50.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Canaccord Genuity Group upped their price target on shares of Stoke Therapeutics from $28.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, January 5th. JPMorgan Chase & Co. raised their price objective on Stoke Therapeutics from $15.00 to $25.00 and gave the stock a “neutral” rating in a report on Monday, November 3rd. Needham & Company LLC boosted their price target on shares of Stoke Therapeutics from $22.00 to $35.00 and gave the company a “buy” rating in a report on Friday, October 10th. Finally, UBS Group set a $50.00 price objective on shares of Stoke Therapeutics in a report on Monday, December 15th.

Insider Buying and Selling

In other Stoke Therapeutics news, insider Barry Ticho sold 5,931 shares of Stoke Therapeutics stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $25.72, for a total value of $152,545.32. Following the transaction, the insider owned 7,195 shares in the company, valued at $185,055.40. The trade was a 45.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Adrian R. Krainer sold 40,472 shares of the stock in a transaction dated Friday, November 14th. The shares were sold at an average price of $26.98, for a total transaction of $1,091,934.56. Following the sale, the director directly owned 364,246 shares of the company’s stock, valued at approximately $9,827,357.08. The trade was a 10.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 104,705 shares of company stock valued at $3,070,910. 9.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Generali Investments Management Co LLC purchased a new stake in Stoke Therapeutics during the 3rd quarter valued at about $41,000. BNP Paribas Financial Markets boosted its position in Stoke Therapeutics by 66.2% in the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after buying an additional 1,668 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in Stoke Therapeutics by 461.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock worth $50,000 after buying an additional 3,591 shares during the period. Osaic Holdings Inc. increased its holdings in Stoke Therapeutics by 263.3% in the 2nd quarter. Osaic Holdings Inc. now owns 7,488 shares of the company’s stock worth $85,000 after buying an additional 5,427 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey boosted its holdings in shares of Stoke Therapeutics by 33.2% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 9,558 shares of the company’s stock valued at $108,000 after acquiring an additional 2,384 shares during the last quarter.

Stoke Therapeutics Trading Down 5.5%

Shares of NASDAQ STOK opened at $29.28 on Friday. Stoke Therapeutics has a 12-month low of $5.35 and a 12-month high of $38.69. The firm’s 50-day moving average price is $30.64 and its 200-day moving average price is $24.16. The stock has a market capitalization of $1.67 billion, a price-to-earnings ratio of 43.70 and a beta of 1.10.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.11). Stoke Therapeutics had a return on equity of 13.28% and a net margin of 19.73%.The company had revenue of $10.63 million for the quarter, compared to the consensus estimate of $6.06 million. On average, equities analysts predict that Stoke Therapeutics will post -2.01 EPS for the current fiscal year.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.